Clinical Trial Results: Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating nivolumab plus ipilimumab in renal medullary carcinoma shows results and has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Medullary Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Kidney Medullary Carcinoma, Loss of INI 1 Protein Expression | Phase 2 | Status: TERMINATED | Results posted: 2026-08-20